Saxenda vs Rybelsus: Cost and Access Head-to-Head
HealthRX.com
Rybelsus is a diabetes drug, so coverage differs
Key numbers
- 11%Share of 136 marketplace plans in 34 states with any coverage for the obesity drugs examined, per a 2018 analysisSource: pubmed.ncbi.nlm.nih.gov, as cited Nov 7, 2026
- 4%Weight loss below this share of baseline body weight by the Saxenda checkpoint means the label says to stopSource: dailymed.nlm.nih.gov, as cited Nov 7, 2026
- 3 mg daily for 30 daysRybelsus starting dose in the label, which the label states is not effective for blood sugar controlSource: dailymed.nlm.nih.gov, as cited Nov 7, 2026
From the public record
Medicaid prescriptions: Saxenda and Rybelsus
State Medicaid programmes paid for 28,807 Saxenda prescriptions and 200,179 Rybelsus prescriptions in 2025, with $34.2M and $256.7M reimbursed before rebates. Figures cover these two brands only.
| Measure | Value |
|---|---|
| Saxenda: prescriptions, 2025 | 28,807 |
| Rybelsus: prescriptions, 2025 | 200,179 |
| Saxenda: reimbursed before rebates | $34.2M |
| Rybelsus: reimbursed before rebates | $256.7M |
| Saxenda: states and territories reporting | 15 |
| Rybelsus: states and territories reporting | 51 |
How this was calculated
Matched Medicaid product codes to the FDA NDC Directory by labeler and product code, kept finished single-ingredient products for each side and summed prescriptions and reimbursement nationally.
Brand-level: Saxenda and Rybelsus only, fee-for-service and managed care, 2025
Counts under 11 are suppressed by CMS and left out, so totals are a floor. Amounts are before rebates. State coverage rules differ for each product. Compounded products are not included.
From the public record
Listed patents: Saxenda and Rybelsus
The FDA Orange Book lists 2 patents not yet expired for Saxenda (latest expiry 2037-07-09) and 14 patents for Rybelsus (latest expiry 2034-05-02). Earliest approvals on file are 2014-12-23 and 2019-09-20.
| Measure | Value |
|---|---|
| Saxenda: listed patents not yet expired | 2 |
| Rybelsus: listed patents not yet expired | 14 |
| Saxenda: latest listed patent expiry | 2037-07-09 |
| Rybelsus: latest listed patent expiry | 2034-05-02 |
| Saxenda: earliest approval on file | 2014-12-23 |
| Rybelsus: earliest approval on file | 2019-09-20 |
How this was calculated
For each brand, selected its single-ingredient Orange Book products by trade name and counted the distinct unexpired patents listed against them.
Brand-level: Orange Book products sold under the names Saxenda and Rybelsus only, files dated 2026-10-09
An approved generic or an expired patent does not show that a generic is on sale. Launch timing also depends on litigation, settlements and supply. Biologics and compounded products are not in the Orange Book.
At a glance
- Saxenda / liraglutide 3 mg once-daily injection for weight management in adults with obesity, adults with overweight plus a comorbidity, and patients 12 and older above 60 kg with obesity [5]
- Rybelsus / oral semaglutide 3, 7 or 14 mg daily for type 2 diabetes and cardiovascular risk reduction; no weight-loss indication [2]
- Generic liraglutide / FDA-approved, including generics that carry the weight-management label [1]
- 2018 coverage analysis / 11% of 136 marketplace plans in 34 states had any coverage for the obesity drugs examined; Medicare excluded obesity drug therapy [4]
- Saxenda checkpoint / label says to assess weight at 16 weeks in adults and stop if less than 4% of baseline is lost [5]
- Rybelsus start / 3 mg daily for 30 days, a dose the label says is not effective for glycemic control [2]
Which has a generic?
Generic liraglutide is FDA-approved [1]. Generics referencing Saxenda carry the weight-management label (Teva ANDA 214568, Biocon ANDA 217063, Cipla ANDA 217234); generics referencing Victoza carry the type 2 diabetes label, such as Hikma ANDA 215503 [1]. Rybelsus is a Novo Nordisk brand tablet; the Drugs@FDA page for its application (NDA 213051) lists only Rybelsus and Ozempic tablets [3].
Indications and coverage data
Saxenda is indicated, with a reduced-calorie diet and more physical activity, to reduce excess body weight and maintain weight reduction long term in adults with obesity, adults with overweight plus at least one weight-related comorbidity, and patients aged 12 and older above 60 kg with obesity [5]. Rybelsus is indicated to improve glycemic control in adults with type 2 diabetes and to reduce major adverse cardiovascular events in adults with type 2 diabetes at high risk [2].
In a 2018 analysis of obesity drugs, Medicare policy excluded drug therapy for obesity, and 11% of 136 marketplace plans in 34 states had some coverage for the drugs examined [4]. That analysis predates current plan rules and does not address Rybelsus's type 2 diabetes indication, so it cannot be used to compare current coverage of the two products [2][4].
Questions worth asking
What the labels require
The Saxenda label says to evaluate weight 16 weeks after starting and to discontinue if an adult has not lost at least 4% of baseline body weight [5]. The Rybelsus label starts at 3 mg daily for 30 days, a dose it states is not effective for glycemic control, then 7 mg for days 31 to 60, then 7 or 14 mg from day 61 depending on glycemic need [2].
Check what you know
Question 1 of 4
Score: 0 right, 0 of 4 answered
Frequently asked questions
Does Saxenda have a generic version?
Is Rybelsus approved for weight loss?
What coverage data exist for these drugs?
Does Rybelsus start at the treatment dose?
References
Show all 7 referencesHide references
- U.S. Food and Drug Administration.
- U.S. National Library of Medicine, DailyMed. Rybelsus and Ozempic tablets (oral semaglutide) prescribing information. Rybelsus and Ozempic tablets (oral semaglutide) label
- Drugs@FDA: FDA-Approved Drugs.
- Gomez G, Stanford FC. US health policy and prescription drug coverage of FDA-approved medications for the treatment of obesity. Int J Obes (Lond). 2018;42(3):495-500.
- U.S. National Library of Medicine, DailyMed. Saxenda injection (liraglutide) prescribing information. Saxenda injection (liraglutide) label
- Pi-Sunyer X, Astrup A, Fujioka K, Greenway F, Halpern A, Krempf M, et al. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. N Engl J Med. 2015;373(1):11-22.
- Pratley R, Amod A, Hoff ST, Kadowaki T, Lingvay I, Nauck M, et al. Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial. Lancet. 2019;394(10192):39-50.